2025
Protocol and design of the REPOSE study: a double-blinded, randomised, placebo-controlled trial to evaluate the efficacy of suvorexant to improve postoperative sleep and reduce delirium severity in older patients undergoing non-cardiac surgery
Fallon J, Hashemaghaie M, Peterson C, Tran D, Wu S, Valdes J, Pedicini N, Adams M, Soltis M, Mansour W, Wright M, Raghunathan K, Treggiari M, Sasannejad C, Devinney M. Protocol and design of the REPOSE study: a double-blinded, randomised, placebo-controlled trial to evaluate the efficacy of suvorexant to improve postoperative sleep and reduce delirium severity in older patients undergoing non-cardiac surgery. BMJ Open 2025, 15: e091099. PMID: 40081971, PMCID: PMC11907038, DOI: 10.1136/bmjopen-2024-091099.Peer-Reviewed Original ResearchMeSH KeywordsAgedAzepinesDeliriumDouble-Blind MethodFemaleHumansMaleOrexin Receptor AntagonistsPostoperative ComplicationsRandomized Controlled Trials as TopicSleepSleep Aids, PharmaceuticalTriazolesConceptsNon-cardiac surgeryTotal sleep timeEfficacy of suvorexantRandomised controlled trialsTwo-sample t-testPostoperative sleepOlder patientsAssociated with prolonged hospitalizationDelirium severityDecrease delirium severityIncreased total sleep timeStudy drug dosePlacebo-controlled trialPostoperative inpatient stayLong-term cognitive impairmentFood and Drug AdministrationOlder surgical patientsPostoperative sleep disturbancePrimary endpoint dataRisk of deliriumT-testOral suvorexantInstitutional review boardPostoperative delirium severityOrexin-1
2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCohort StudiesConnecticutCOVID-19COVID-19 SerotherapyFemaleHospital MortalityHumansImmunization, PassiveInpatientsLength of StayMaleMiddle AgedPropensity ScoreRandomized Controlled Trials as TopicSARS-CoV-2Treatment OutcomeConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2008
Intensive insulin therapy and mortality in critically ill patients
Treggiari MM, Karir V, Yanez ND, Weiss NS, Daniel S, Deem SA. Intensive insulin therapy and mortality in critically ill patients. Critical Care 2008, 12: r29. PMID: 18312617, PMCID: PMC2374630, DOI: 10.1186/cc6807.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesCritical CareDose-Response Relationship, DrugFemaleGlycemic IndexHospital MortalityHumansHypoglycemiaHypoglycemic AgentsInsulinIntensive Care UnitsLength of StayMaleMiddle AgedMultiple Organ FailureRandomized Controlled Trials as TopicRegression AnalysisSeverity of Illness IndexTrauma CentersConceptsIntensive care unitHospital mortalityIll patientsSequential Organ Failure Assessment scoreOrgan Failure Assessment scorePost-cardiac surgery patientsLevel 1 trauma centerExcess hospital mortalityAdjusted hospital mortalityOccurrence of hypoglycemiaTight glycemic controlMain study endpointMultivariable regression analysisPeriod IIICU lengthPeriod IIICohort studyInsulin therapySurgery patientsGlycemic controlOrgan dysfunctionStudy endpointCare unitTrauma centerStudy population
2003
Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage.
Treggiari MM, Walder B, Suter PM, Romand JA. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. Journal Of Neurosurgery 2003, 98: 978-84. PMID: 12744357, DOI: 10.3171/jns.2003.98.5.0978.Peer-Reviewed Original ResearchMeSH KeywordsBlood PressureBlood VolumeBrainBrain IschemiaCombined Modality TherapyHemodilutionHumansRandomized Controlled Trials as TopicSubarachnoid HemorrhageSurvival RateVasospasm, IntracranialConceptsDelayed ischemic neurological deficitsIschemic neurological deficitsHemodilution therapyNeurological deficitsSubarachnoid hemorrhageMethodological qualitySystematic reviewSummary relative risk estimatesRisk of deathMajor end pointsInternal validity scoreRelative risk estimatesStudy methodological qualityRandom-effects modelClinical vasospasmSymptomatic vasospasmCerebral vasospasmRegister searchMAIN OUTCOMEValidity scoresReference listsPaucity of informationVasospasmEnd pointRisk estimates
2002
Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age?
Weiss NS, Treggiari MM. Postmenopausal hormone use and skeletal fracture: does the size of the benefit decrease with increasing age? Obstetrics And Gynecology 2002, 100: 364-8. PMID: 12151165, DOI: 10.1016/s0029-7844(02)02046-x.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBone DensityFemaleFractures, SpontaneousHip FracturesHormone Replacement TherapyHumansIncidenceMiddle AgedOsteoporosis, PostmenopausalPrognosisRandomized Controlled Trials as TopicRisk FactorsConceptsLong-term hormone useOlder postmenopausal womenPostmenopausal womenHormone useFracture riskYounger postmenopausal womenPostmenopausal hormone useSurrogate end pointsBone mineral densityUse of hormonesHormone therapySkeletal benefitsRandomized trialsSuch therapyMineral densitySkeletal fracturesAbsolute reductionEnd pointStudy of hormonesWomenHealth careTrialsAgeTrue declineRisk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply